With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking to its projection to generate sales of more than 40 billion pounds sterling ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including Switzerland and Canada.

Key Takeaways Blenrep plus Velcade and dexamethasone significantly improves overall survival in relapsed/refractory multiple myeloma compared to Darzalex-based regimens. The DREAMM-7 trial met its ...

BLENREP employs a multi-faceted mechanism of action and is directed toward BCMA, a cell-surface protein that plays an important role in the survival of plasma cells and is expressed on multiple ...

(Reuters) -The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood plasma cells, the British drugmaker said on Thursday. EU ...

Blenrep is a humanized, afucosylated, IgG1 anti-B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent, monomethyl auristatin F. The Food and Drug Administration ...

Treatment of Blenrep (belantamab mafodotin) in combination with Velcade (bortezomib) plus dexamethasone significantly improved progression-free survival compared with standard treatment for patients ...

Though Blenrep is also approved in Europe, the drug’s sales have been significantly impacted owing to its withdrawal from the U.S. markets. Blenrep sales plunged 67% at constant exchange rate in ...

Blenrep combo nearly tripled PFS to 36.6 months vs 13.4 months in DREAMM-7. Blenrep cut risk of death by 42% vs comparator in DREAMM-7 at 39.4-month median follow-up. Up Next: Get 5 Dark Horse ...

BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome ...

GSK ’s GSK 0.30% blood-cancer drug Blenrep showed positive overall survival data in a late-stage trial, increasing the likelihood for the treatment to return to market next year. The data showed ...